FDA advises consumers not to use Blue Steel and Hero dietary supplements

Fidanacogene elaparvovec-dzkt (Beqvez) is a 1 time treatment that allows patients with hemophilia B to produce factor IX themselves.

Don Arthur, RPh, discusses what lays ahead in independent pharmacy, from clinical care to success stories.

The approval for tovorafenib (Ojemda) was based on data from the phase 2 FIREFLY-1 trial, in which the therapy demonstrated an overall repose rate of 67%.

Learn more about the ins and outs of pharmacy ownership from the experts at First Financial Bank.

Check out important updates from the FDA for the week of April 15.

This approval is the second biosimilar approval for manufacturer Alvotech.